CUMYL-CH-MEGACLONE
CUMYL-CH-MEGACLONE structure.png
Legal status
Legal status
Identifiers
  • 2,5-Dihydro-2-(1-methyl-1-phenylethyl)-5-(cyclohexylmethyl)-1H-pyrido[4,3-b]indol-1-one
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC27H30N2O
Molar mass398.54 g·mol−1
3D model (JSmol)
  • CC(C)(C1=CC=CC=C1)N2C=CC3=C(C2=O)C4=CC=CC=C4N3CC5CCCCC5
  • InChI=1S/C27H30N2O/c1-27(2,21-13-7-4-8-14-21)29-18-17-24-25(26(29)30)22-15-9-10-16-23(22)28(24)19-20-11-5-3-6-12-20/h4,7-10,13-18,20H,3,5-6,11-12,19H2,1-2H3
  • Key:CGHCGYCTOLWAPL-UHFFFAOYSA-N

CUMYL-CH-MEGACLONE (CUMYL-CHMGACLONE, SGT-270) is a gamma-carboline based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Hungary in December 2018.[1][2][3]

See also

References

  1. ^ Alam RM, Keating JJ (March 2020). "Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists". Drug Testing and Analysis. 12 (3): 297–315. doi:10.1002/dta.2752. PMID 31854124. S2CID 209417068.
  2. ^ Haschimi B, Giorgetti A, Mogler L, Nagy TZ, Kramer S, Halter S, et al. (June 2020). "The Novel Psychoactive Substance Cumyl-CH-MEGACLONE: Human Phase-I Metabolism, Basic Pharmacological Characterization, and Comparison to Other Synthetic Cannabinoid Receptor Agonists with a γ-Carboline-1-one Core". Journal of Analytical Toxicology. 45 (3): 277–290. doi:10.1093/jat/bkaa065. PMID 32514544.
  3. ^ Institóris L, Kovács K, Sija É, Berkecz R, Körmöczi T, Németh I, Elek I, Bakos Á, Urbán I, Pap C, Kereszty É (June 2021). "Clinical symptoms and blood concentration of new psychoactive substances (NPS) in intoxicated and hospitalized patients in the Budapest region of Hungary (2018-19)". Clinical Toxicology. Philadelphia, Pa.: 1–7. doi:10.1080/15563650.2021.1928162. PMID 34080493. S2CID 235321374.